Tilmanocept
- Generic Name
- Tilmanocept
- Brand Names
- Lymphoseek
- Drug Type
- Small Molecule
- CAS Number
- 1185986-76-8
- Unique Ingredient Identifier
- MDU8BQ474H
- Background
Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)).
- Associated Conditions
- Breast Cancer, Melanoma, Oral Cancer
FDA Approves Lymphoseek for Head and Neck Cancer Lymphatic Mapping
• The FDA has approved Navidea Biopharmaceuticals' Lymphoseek for sentinel lymph node biopsy guidance in head and neck cancer patients with squamous cell carcinoma of the oral cavity.
• Lymphoseek, a radioactive diagnostic imaging agent, was initially approved in 2013 for locating lymph nodes in breast cancer and melanoma patients.
• This expanded indication marks the second approval for Lymphoseek in the U.S., broadening its clinical utility in cancer staging.
• Navidea has a distribution partnership with Cardinal Health for Lymphoseek, which was first launched in the U.S. in May 2013.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath